Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation

Bachhav, Yogeshwar; Patravale, Vandana

doi:10.2478/v10007-010-0020-0

Abstract

Skin delivery of NSAIDs offers several advantages over the oral route associated with potential side effects. In the present investigation, topical gel of meloxicam (MLX) was formulated using N-methyl pyrrolidone (NMP) as a solubilizer and Carbopol Ultrez 10® as a gelling polymer. MLX gel was evaluated with respect to different physicochemical parameters such as pH, viscosity and spreadability. Irritation potential of MLX gel was studied on rabbits. Permeation of MLX gel was studied using freshly excised rat skin as a membrane. Anti-inflammatory activity of MLX gel was studied in rats and compared with the commercial formulation of piroxicam (Pirox® gel, 0.5% m/m). Accelerated stability studies were carried out for MLX gel for 6 months according to ICH guidelines. MLX gel was devoid of any skin irritation in rabbits. After 12 h, cumulative permeation of MLX through excised rat skin was 3.0 ± 1.2 mg cm^-2 with the corresponding flux value of 0.24 ± 0.09 mg cm^-2 h^-1. MLX gel exhibited significantly higher anti-inflammatory activity in rats compared to Pirox® gel. Physicochemically stable and non-irritant MLX gel was formulated which could deliver significant amounts of active substance across the skin in vitro and in vivo to elicit the anti-inflammatory activity.

References

S. Noble and J. A. Balfour, Meloxicam, Drugs 51 (1996) 424-430; DOI: 10.2165/00003495-199651030-00007.10.2165/00003495-199651030-00007
Search in Google Scholar
N. M. Davies and N. M. Skjodt, Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug, Clin. Pharmacokinet. 36 (1999) 115-126; DOI: 2165/00003088-199936020-00003.
Search in Google Scholar
B. J. Gates, T. T. Nguyen, S. M. Setter and N. M. Davies, Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety, Expert Opin. Pharmacother. 6 (2005) 2117-2140; DOI: 10.1517/14656566.6.12.2117.10.1517/14656566.6.12.2117
Search in Google Scholar
M. R. Prausnitz, S. Mitragotri and R. Langer, Current status and future potential of transdermal drug delivery, Nat. Rev. Drug Discov. 3 (2004) 115-124; DOI: 10.1038/nrd1304.10.1038/nrd1304
Search in Google Scholar
E. Beetge, J. D. Plessis, D. G. Muller, C. Goosen and F. J. Van Rensburg, The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAIDs on their transdermal absorption, Int. J. Pharm. 193 (2000) 261-264; DOI: 10.1016/S0378-5173(99)00340-3.10.1016/S0378-5173(99)00340-3
Search in Google Scholar
P. Stei, B Kruss, J. Weigleb and V. Trach, Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration, Br. J. Rheumatol. 35 (1996) 44-50; DOI: 10.1093/rheumatology/35.suppl_1.44.10.1093/rheumatology/35.suppl_1.44
Search in Google Scholar
R. Jantharaprapap and G. Stagni, Effects of penetration enhancers on in vitro permeability of meloxicam gels, Int. J. Pharm. 343 (2007) 26-33; DOI: 10.1016/j.ijpharm.2007.04.011.10.1016/j.ijpharm.2007.04.011
Search in Google Scholar
J. S. Chang, Y. B. Huang, S. S. Hou, R. J. Wang, P. C. Wu and Y. H. Tsai, Formulation optimization of meloxicam sodium gel using response surface methodology, Int. J. Pharm. 338 (2007) 48-54; DOI: 10.1016/j.ijpharm.2007.01.033.10.1016/j.ijpharm.2007.01.033
Search in Google Scholar
Y. Yuan, S. M. Li, F. K. Mo and D. F. Zhong, Investigation of microemulsion system for transdermal delivery of meloxicam, Int. J. Pharm. 321 (2006) 117-123; DOI: 10.1016/j.ijpharm.2006.06.021.10.1016/j.ijpharm.2006.06.021
Search in Google Scholar
ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva 2005, Switzerland.
Search in Google Scholar
M. Joshi and V. Patravale, Nanostructured lipid carrier (NLC) based gel of celecoxib, Int. J. Pharm. 346 (2008) 124-132; DOI: 10.1016/j.ijpharm.2007.05.060.10.1016/j.ijpharm.2007.05.060
Search in Google Scholar
United States Pharmacopoeia 24, National Formulary 19, USP Pharmacopoeial Convention, Rockwille (MD) 2000.
Search in Google Scholar
ICH Topic Q1 A (R2) Stability Testing of new Drug Substances and Products (2005), International Conference on Harmonisation of Technical requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
Search in Google Scholar
B. J. Vermeer, Skin irritation and sensitization, J. Control. Rel. 15 (1991) 261-265; DOI: 10.1016/0168-3659(91)90117-V.10.1016/0168-3659(91)90117-V
Search in Google Scholar
E. Pontiki and D. Hadjipavlou-Litina, Synthesis of phenyl-substituted amides with antioxidant and anti-inflammatory activity as novel lipoxygenase inhibitors, Med. Chem. 3 (2007) 175-186; DOI: 10.2174/157340607780059512.10.2174/15734060778005951217348855
Search in Google Scholar
M. D. Joshi and V. B. Patravale, Formulation and evaluation of nanostructured lipid carrier (NLC) based gel of valdecoxib, Drug Dev. Ind. Pharm. 32 (2006) 911-918; DOI: 10.1080/03639040600814676.10.1080/0363904060081467616954103
Search in Google Scholar
R. Sanghavi, R. Narazaki, S. G. Machatha and S. H. Yalkowsky, Solubility improvement of drugs using N-methyl pyrrolidone, AAPS PharmSci Tech. 9 (2008) 366-376; DOI: 10.1208/s12249-008-9050-z.10.1208/s12249-008-9050-z297693518431671
Search in Google Scholar
P. J. Lee, R. Langer and V. P. Shastri, Role of N-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport, J. Pharm. Sci. 94 (2005) 912-917; DOI: 10.1002/jps.20291.10.1002/jps.2029115736187
Search in Google Scholar
A. C. Williams and B. W. Barry, Penetration enhancers, Adv. Drug Del. Rev. 56 (2004) 603-618; DOI:10.1016/j.addr.2003.10.025.10.1016/j.addr.2003.10.02515019749
Search in Google Scholar

Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation

Abstract

Paradigm

My account